Enweida (envafolimab)

P1, N=57, Recruiting, Kangabio AUSTRALIA LTD PTY

P2, N=30, Not yet recruiting, Fudan University

P2, N=15, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

Envafolimab combined with chemotherapy as a first-line treatment for ES-SCLC yielded favorable clinical efficacy with a manageable safety profile, indicating that it may be a promising treatment modality.

In this retrospective, single-arm design study, 36 LARC patients (T3+/N1-2/M0) received long-course radiotherapy (50.4 Gy/28 fractions) with capecitabine, followed by two cycles of XELOX chemotherapy and envafolimab...This approach enhances cytotoxic immunity while addressing immunosuppressive barriers. Further studies should explore strategies to overcome TME resistance.

This process effectively alleviates immunosuppression in the TME and enhances the activation and proliferation of tumor-specific T cells. Experimental results demonstrated that CXCL12-KN035-expressing bacteria significantly inhibit tumor growth and metastasis through the synergistic action of the chemokine and nanobody, establishing a novel degradation-centric paradigm for bacteria-mediated tumor therapy beyond transient blockade.

P2, N=23, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

P2, N=43, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences

P2, N=100, Not yet recruiting, Peking University | Trial completion date: Aug 2026 --> Jul 2028 | Initiation date: Jan 2025 --> Jul 2025 | Trial primary completion date: Aug 2025 --> Jul 2027

However, a growing number of additional PD-1/PD-L1 inhibitors, including AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab, are currently under investigation, offering new possibilities for the expansion of treatment options...Additionally, it explores key challenges such as primary and acquired resistance, limited efficacy in microsatellite-stable (MSS) CRC, and the complexities of combination strategies aimed at enhancing immunotherapeutic responses. By addressing these obstacles and highlighting prospects, this review provides insights into the evolving landscape of PD-1/PD-L1-targeted therapies in CRC and their potential to improve patient outcomes.

Envafolimab demonstrates a tolerable safety profile and favorable efficacy. With its subcutaneous formulation, Envafolimab shows promising potential for treating advanced lung cancer.

Overall, the incidence of adverse reactions in the combination group was greatly decreased than that in the D-TAE group (P<0.05). Drug-loaded microsphere interventional embolization combined with sorafenib and envafolimab has certain efficacy and acceptable safety in treating intermediate and late-stage renal tumor, providing a new treatment option for patients with renal cell carcinoma.